Venous thromboembolism (VTE), which comprises deep vein thrombosis (DVT) and pulmonary embolism (PE), and arterial thromboembolism (ATE), which includes myocardial infarction, ischemic stroke, systemic embolism, and peripheral arterial events, are common among hospitalized patients with coronavirus disease-2019 (COVID-19) and are major causes of morbidity and mortality. [1,2] The incidence of VTE in this population has been estimated between 5.5% to 14.1%, and such patients have a more than two-fold higher risk for developing VTE than matched controls [2,3].
